Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Oral Paclitaxel in Advanced HER2-Negative Breast Cancer
NCT07602907Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel oral solution in breast cancer (5 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Optimal Tolerated Dose at 7 days and Disease Control Rate at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
paclitaxel oral solution
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07602907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602907.